Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Brentuximab Vedotin Plus Bendamustine for Relapsed/Refractory Follicular Lymphoma

NCT04587687 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT04587687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04587687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Brentuximab Vedotin Plus Bendamustine for Relapsed/Refractory Follicular Lymphoma
Lead sponsor
University of California, Davis
Phase
Phase 2
Overall status
Recruiting
Start date
December 4, 2020
Completion date
May 31, 2028
Enrollment
23 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent follicular lymphoma, refractory follicular lymphoma